Illumina (NASDAQ:ILMN) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Illumina (NASDAQ:ILMN) issued its quarterly earnings data on Thursday. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08, FiscalAI reports. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the firm posted $1.19 EPS. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina updated its FY 2026 guidance to 5.300-5.400 EPS.

Here are the key takeaways from Illumina’s conference call:

• Q2 exceeded expectations: Revenue rose 9.5% year over year to $1.16 billion, organic rest-of-world growth was 8.1%, and non-GAAP EPS increased 10% to $1.31. Operating margin also came in above guidance despite higher freight and memory costs.
• Clinical demand remains the primary growth engine, with clinical sequencing consumables up 15% outside China and U.S.-Canada growth above 20%. Illumina placed more than 95 NovaSeq X instruments in the quarter, expanding the installed base and supporting future consumables pull-through.
• Management raised full-year 2026 guidance to rest-of-world organic revenue growth above 5%, reported revenue of $4.60 billion-$4.64 billion, and non-GAAP EPS of $5.30-$5.40. The company continues to target high-single-digit revenue growth in 2027.
• Research and academic customers remain cautious amid funding uncertainty; research and applied consumables declined 7% in the quarter, and Illumina still expects mid- to high-single-digit declines in this market for 2026.
• Illumina is expanding beyond core sequencing through spatial biology, proteomics, and BioInsite. The Billion Cell Atlas has delivered more than 300 million cells, generated initial revenue, and added three partners after quarter-end, bringing the total to six, although management characterized the opportunity as still early.

Illumina Stock Performance

Shares of ILMN traded down $5.53 during trading hours on Friday, hitting $199.56. The company’s stock had a trading volume of 2,260,349 shares, compared to its average volume of 1,889,744. The business has a 50 day simple moving average of $175.49 and a two-hundred day simple moving average of $146.83. Illumina has a 52-week low of $88.00 and a 52-week high of $205.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The company has a market cap of $30.19 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.88 and a beta of 1.47.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported second-quarter revenue of $1.16 billion, up approximately 9.5% year over year, while non-GAAP EPS of $1.31 exceeded the $1.23 analyst consensus. Clinical demand and continued NovaSeq X placements were key growth drivers. Illumina Q2 2026 Financial Results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $4.60 billion–$4.64 billion and non-GAAP EPS guidance to $5.30–$5.40, above the prior outlook and roughly ahead of consensus expectations. Illumina Q2 Outlook
• Positive Sentiment: Stifel Nicolaus raised its price target from $155 to $225 and upgraded the stock to “buy,” citing improved growth prospects. Eli Lilly also joined Illumina’s Billion Cell Atlas initiative, potentially strengthening the company’s position in genomic data and drug discovery. Stifel Price Target
• Neutral Sentiment: Analyst views remain mixed: the recent median price target was $185, below the stock’s recent trading level, although several firms maintain targets near $200.
• Neutral Sentiment: Institutional positioning was divided, with 375 investors adding shares and 402 reducing positions in the latest reported quarter.
• Negative Sentiment: Greater China revenue fell 12% year over year, reflecting continuing China-related restrictions and demand pressure.
• Negative Sentiment: Full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%, while management indicated that year-over-year NovaSeq X instrument-placement growth may moderate in the second half.
• Negative Sentiment: Reported insider activity was heavily weighted toward selling: 41 sales versus one purchase over the past six months, including substantial sales by Keith Meister. This may add to investor caution, although insider transactions can reflect personal liquidity needs.

Insider Buying and Selling at Illumina

In related news, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the transaction, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. This trade represents a 3.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Compound Planning Inc. purchased a new stake in shares of Illumina in the fourth quarter worth about $211,000. Invesco Ltd. increased its holdings in Illumina by 97.0% during the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after acquiring an additional 1,352,731 shares during the period. Axxcess Wealth Management LLC purchased a new stake in Illumina in the 4th quarter worth approximately $215,000. Corient Private Wealth LLC lifted its stake in Illumina by 927.7% in the 4th quarter. Corient Private Wealth LLC now owns 128,746 shares of the life sciences company’s stock worth $16,886,000 after purchasing an additional 116,219 shares in the last quarter. Finally, Alberta Investment Management Corp boosted its holdings in Illumina by 242.5% in the 4th quarter. Alberta Investment Management Corp now owns 13,700 shares of the life sciences company’s stock valued at $1,797,000 after purchasing an additional 9,700 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Citigroup increased their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. TD Cowen reiterated a “hold” rating on shares of Illumina in a research note on Wednesday, July 15th. Leerink Partners boosted their price target on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Finally, Piper Sandler lifted their price objective on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $168.71.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.